724 related articles for article (PubMed ID: 24211427)
21. Giant osteoclast formation and long-term oral bisphosphonate therapy.
Weinstein RS; Roberson PK; Manolagas SC
N Engl J Med; 2009 Jan; 360(1):53-62. PubMed ID: 19118304
[TBL] [Abstract][Full Text] [Related]
22. [Bisphosphonates: pharmacology and use in the treatment of osteoporosis].
Kishimoto H
Nihon Rinsho; 1998 Jun; 56(6):1531-6. PubMed ID: 9648477
[TBL] [Abstract][Full Text] [Related]
23. [[Antiresorptive agents in the treatment of osteoporosis].
Novak S
Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
[TBL] [Abstract][Full Text] [Related]
24. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
Benford HL; McGowan NW; Helfrich MH; Nuttall ME; Rogers MJ
Bone; 2001 May; 28(5):465-73. PubMed ID: 11344045
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonates: mechanism of action and role in clinical practice.
Drake MT; Clarke BL; Khosla S
Mayo Clin Proc; 2008 Sep; 83(9):1032-45. PubMed ID: 18775204
[TBL] [Abstract][Full Text] [Related]
26. Glucocorticoids and the osteoclast.
Teitelbaum SL
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S37-9. PubMed ID: 26458014
[TBL] [Abstract][Full Text] [Related]
27. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P; Nguyen H; Barbier A; Baron R
J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
[TBL] [Abstract][Full Text] [Related]
28. Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors.
Tanaka M; Hosoya A; Mori H; Kayasuga R; Nakamura H; Ozawa H
J Bone Miner Metab; 2018 Jan; 36(1):54-63. PubMed ID: 28243795
[TBL] [Abstract][Full Text] [Related]
29. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
30. Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro.
Heervä E; Peltonen S; Svedström E; Aro HT; Väänänen K; Peltonen J
Bone; 2012 Mar; 50(3):798-803. PubMed ID: 22226973
[TBL] [Abstract][Full Text] [Related]
31. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
Cheung MS; Glorieux FH; Rauch F
J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
[TBL] [Abstract][Full Text] [Related]
32. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
33. The backbone of progress--preclinical studies and innovations with zoledronic acid.
Green JR; Guenther A
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of indolyl bisphosphonates as anti-bone resorptive and anti-leishmanial agents.
Singh US; Shankar R; Kumar A; Trivedi R; Chattopadhyay N; Shakya N; Palne S; Gupta S; Hajela K
Bioorg Med Chem; 2008 Sep; 16(18):8482-91. PubMed ID: 18752963
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates: how do they work?
Papapoulos SE
Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
[TBL] [Abstract][Full Text] [Related]
37. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.
Weinstein RS; Chen JR; Powers CC; Stewart SA; Landes RD; Bellido T; Jilka RL; Parfitt AM; Manolagas SC
J Clin Invest; 2002 Apr; 109(8):1041-8. PubMed ID: 11956241
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonates use in children.
Sebestyen JF; Srivastava T; Alon US
Clin Pediatr (Phila); 2012 Nov; 51(11):1011-24. PubMed ID: 22935217
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacology of bone resorption inhibitor].
Menuki K; Sakai A
Nihon Rinsho; 2015 Oct; 73(10):1634-8. PubMed ID: 26529923
[TBL] [Abstract][Full Text] [Related]
40. A useful method to evaluate bone resorption inhibitors, using osteoclast-like multinucleated cells.
Sugawara K; Hamada M; Hosoi S; Tamaoki T
Anal Biochem; 1998 Jan; 255(2):204-10. PubMed ID: 9451505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
